ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

“You Can’t Legislate Biology,” Higginson Tells AACI Members

February 9, 1979

Broder Issues Clinical Alert on 5-FU Levamisle Survival Advantage for Dukes C Colon Cancer

October 6, 1989

NCI Posts Website Usability Research, Information Online.

January 12, 2001

Nominations sought for NCI consumer liaison group.

January 9, 2004

Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression

November 30, 2012

Oncology Nurse “Cinderella’s” Need Specialty Status

November 23, 1974